While the numbers have been in-line, the company has headroom for better growth, says Surajit Pal, Pharma analyst at Prabhudas Lilladher. Capacity constraints for approved products continue to weigh on Aurobindo.
first published: Aug 24, 2016 12:39 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty extends fall to the 3rd day, breaks below 26,100 | Closing Bell
Live: Can Nifty hold 26,200, break 2-day dull performance? | Opening Bell
Live: Nifty breaks below 26,200 on expiry day, broader markets underperform | Closing Bell
Live: Will Nifty's weakness continue for the second straight day? | Opening Bell
